At this meeting, committee members will:
-Discuss future needs in patient safety of cell-based therapies.
-Learn about evolving safety tools and applied techniques for in vivo cell tracking and tumorigenicity risk evaluation of cell-based products.
-Explore opportunities for international collaborations in cell therapy development and use.
-Network with other industry colleagues in the sector from academia, industry, and regulatory bodies.
HESI’s Cell Therapy–TRAcking, Circulation, & Safety (CT-TRACS) Committee is honored to have presented the first workshop of the new Cell and Gene Therapy Catapult seminar series.
Topics and Learning Objectives:
1. Future needs in patient safety of cell-based therapies. Identify challenges and opportunities to enhance the accuracy and efficiency of safety assessment of cell therapy products. Perspectives from a broad range of stakeholders from design to implementation settings.
2. Evolving safety tools and applied safety techniques. Learn about in vivo cell tracking approaches and their role in supporting clinical translation, as well as methods for evaluating the potential tumorigenicity risk of cell-based therapeutic products.
3. Role of collaboration in cell therapy development and use. Explore international opportunities to bridge stakeholders and improve our ability to develop and implement effective standards.